In a study published in Nature Genetics, researchers created a network of interacting proteins with which they identified groups of proteins interacting with genes that have been linked through GWAS to over 1,000 human traits from 21 therapeutic areas.
Open Targets researchers use CRISPR and mini tumours to discover more about how mutations in the IFN-gamma immune pathway affect the development of colorectal cancer.
Genentech, a subsidiary of the Roche Group, brings its expertise in biotechnology to the consortium.
Continuing their previous work published in 2019, a team of Open Targets researchers create a one-of-a-kind, detailed map of gene expression dynamics during the T cell activation process, uncovering new biology and prioritising targets for new therapies.
Scientists at Open Targets create a molecular map of myeloid differentiation using over 470,000 human induced pluripotent stem cells, showing that the differentiated cells are able to acquire definitive tissue-resident identities.. This will be an important resource to explore myelopoiesis and new therapeutic opportunities.
Pfizer will contribute its unique expertise in oncology, immunology, and metabolic disorders, complementing the expertise of our five current partners.
An Open Targets project, published in Nature Reviews Drug Discovery, established a new framework to assess whether human proteins could be targeted with Proteolysis Targeting Chimeras (PROTACs).
Open Targets researchers define how factors such as age, sex, and clinical pathology affect microglia, a critically important cell in the development and diseases of the human central nervous system.
Our new, next-generation Open Targets Platform is the culmination of over two years of work. It reinvents the best of the old Platform with a redesigned experience, improved usability, based on powerful modern technologies.
For the first time, a collaboration between Open Targets and the Broad Institute integrated independent CRISPR-Cas9 screens performed at each institution, providing greater statistical power to cancer- and subtype-specific analyses.
A systematic survey of 215 iPS cell lines obtained from HipSci identified molecular signatures to select the best lines to use in the study of neuronal development, unlocking the potential of iPSC lines to study otherwise inaccessible cell states.
An Open Targets paper identifies 37 regions associated with Alzheimer’s disease, including 4 novel ones, and prioritises a list of genes within those regions that may alter Alzheimer’s disease risk.
In response to the COVID-19 pandemic, the Open Targets team created a tool to support drug target identification and drug repurposing for COVID-19. The information contained in this platform has since been integrated into the Open Targets Platform.
The Locus-to-gene (L2G) machine-learning scoring method is integrated in the Open Targets Genetics Platform. It reflects the likelihood that a gene is causal for the trait in question. The method was published in Nature Genetics in October 2021.
Open Targets researchers created a database of uniformly processed gene expression and splicing QTLs from a wide range of human studies. The method was published in September 2021.
A team of researchers at Open Targets analyse the chromatin activity of immune disease-associated variants at different stages of T cell and macrophage activation, and show that such variants have a role in early rather than late activation of memory T cells.
Colleagues from all of our consortium partners gathered at the Wellcome Genome Campus in Hinxton, UK to celebrate 5 years of Open Targets and plan the milestones for our next 5 years.
Open Targets researchers map health and asthmatic lung tissue to uncover new drug targets for treating asthma
Open Targets publishes results from its landmark experimental project where CRISPR technology was used in over 300 cancer models to discover thousands of key genes essential for cancer’s survival.
Ian Dunham is appointed Director for Open Targets and will continue to focus on the delivery of our established research programme that aims to exploit advances in genetics and genomics for drug target identification and prioritisation.
Sanofi joins the consortium and brings its expertise in immunology, oncology, neurosciences and diabetes to help us identify potential drug targets.
During ASHG 2018, we officially released Open Targets Genetics, a new web tool that allows users to browse gene-variant-trait relationships from UK Biobank data and GWAS Catalog studies.
Rolf Apweiler becomes the Interim Director for Open Targets and continues to foster new partnerships and collaborations to drive drug discovery.
Celgene joins Open Targets and brings its expertise in developing innovative therapies for patients with cancer, immune-inflammatory, and other unmet medical needs.
Takeda joins Open Targets and brings its expertise in oncology, gastroenterology and central nervous system therapeutic areas, along with vaccines.
To celebrate the release of our first experimental data, CTTV rebrands itself as Open Targets but maintains its focus on helping researchers identify and prioritise potential therapeutic drug targets.
Biogen joins Open Targets and brings its expertise in innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.
Underscoring our commitment to share our data openly to benefit the broader scientific community, we launched a new web platform to help researchers identify therapeutic targets for new and repurposed medicines.
After leading the development of the Immunochip genotyping array and playing an important role in UK10K Dr Jeffrey Barrett is appointed as the founding Director of the Centre for Therapeutic Target Validation (CTTV)
The predecessor to Open Targets was founded in March 2014 when the European Bioinformatics Institute (EMBL-EBI), the Wellcome Sanger Institute, and GSK came together to build a partnership that would focus on target identification, prioritisation, and validation.